Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis
Conditions
Interventions
ME1111 Solution, Low strength
ME1111 Solution, High strength
+1 more
Locations
31
United States
Birmingham, Alabama, United States
Encinitas, California, United States
San Diego, California, United States
San Francisco, California, United States
Santa Rosa, California, United States
Denver, Colorado, United States
Start Date
December 19, 2013
Primary Completion Date
October 28, 2015
Completion Date
March 1, 2016
Last Updated
March 18, 2024
NCT06689852
NCT00233493
NCT06175013
NCT06254027
NCT05809297
NCT05110638
Lead Sponsor
Meiji Seika Pharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions